

Hana M El Sahly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7414802/publications.pdf>

Version: 2024-02-01

69
papers

13,250
citations

218381

26
h-index

118652

62
g-index

75
all docs

75
docs citations

75
times ranked

20991
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
2	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 795-807.	13.9	1,398
3	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	6.0	788
4	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	13.9	418
5	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
6	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	13.9	338
7	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
8	Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations. <i>Clinical Infectious Diseases</i> , 2006, 43, 1135-1142.	2.9	140
9	Postacute COVID-19: An Overview and Approach to Classification. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa509.	0.4	128
10	Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 237.	3.8	124
11	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. <i>Cell Reports Medicine</i> , 2022, 3, 100679.	3.3	100
12	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i> , 2015, 33, 5225-5234.	1.7	92
13	Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 Months_{title}>A Randomized Trial</sub>. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1532.	3.8	90
14	Safety and immunogenicity of a candidate parvovirus B19 vaccine. <i>Vaccine</i> , 2011, 29, 7357-7363.	1.7	75
15	<i>Mycobacterium simiae</i> Pseudo-outbreak Resulting from a Contaminated Hospital Water Supply in Houston, Texas. <i>Clinical Infectious Diseases</i> , 2002, 35, 802-807.	2.9	73
16	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	2.0	63
17	MF59 as a vaccine adjuvant: a review of safety and immunogenicity. <i>Expert Review of Vaccines</i> , 2010, 9, 1135-1141.	2.0	56
18	Epidemiologic Differences between United States- and Foreign-Born Tuberculosis Patients in Houston, Texas. <i>Journal of Infectious Diseases</i> , 2001, 183, 461-468.	1.9	50

#	ARTICLE	IF	CITATIONS
19	Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. <i>New England Journal of Medicine</i> , 2021, 385, 2485-2487.	13.9	49
20	Pandemic H5N1 influenza vaccine development: an update. <i>Expert Review of Vaccines</i> , 2008, 7, 241-247.	2.0	44
21	The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 106-108.	1.5	42
22	Drug-resistant tuberculosis: A disease of target populations in Houston, Texas. <i>Journal of Infection</i> , 2006, 53, 5-11.	1.7	41
23	Mortality associated with central nervous system tuberculosis. <i>Journal of Infection</i> , 2007, 55, 502-509.	1.7	40
24	Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. <i>American Journal of Medicine</i> , 2019, 132, 437-446.	0.6	33
25	Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial. <i>Vaccine</i> , 2014, 32, 1019-1028.	1.7	32
26	Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the <i>Francisella tularensis</i> live vaccine strain "A" A phase 2 randomized clinical Trial. <i>Vaccine</i> , 2017, 35, 4730-4737.	1.7	30
27	Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2012, 205, 703-712.	1.9	26
28	Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy352.	0.4	26
29	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. <i>Nature Medicine</i> , 2022, 28, 823-830.	15.2	26
30	Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 1127-1137.	2.9	23
31	Optimizing PCR Detection of Zika Virus from Various Body Fluids. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 427-433.	0.6	22
32	Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. <i>Vaccine</i> , 2017, 35, 1675-1682.	1.7	17
33	Incidence of Moxifloxacin Resistance in Clinical <i>Mycobacterium tuberculosis</i> Isolates in Houston, Texas. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2942-2945.	1.8	15
34	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	2.0	15
35	Survival of an AIDS patient after infection with <i>Acanthamoeba</i> sp. of the central nervous system. <i>Infection</i> , 2017, 45, 715-718.	2.3	14
36	Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. <i>Vaccine</i> , 2018, 36, 606-614.	1.7	14

#	ARTICLE	IF	CITATIONS
37	Impact of the SARS-CoV-2 pandemic on health-care workers. <i>Hospital Practice</i> (1995), 2020, 48, 161-164.	0.5	13
38	Reliability and Validity of an Adapted and Translated Version of the Mullen Scales of Early Learning (AT&MSEL) in Rural Guatemala. <i>Child: Care, Health and Development</i> , 2020, 46, 327-335.	0.8	13
39	Receptive language skills among young children in rural Guatemala: The relationship between the Test de Vocabulario en Imagenes Peabody and a translated and adapted version of the Mullen Scales of Early Learning. <i>Child: Care, Health and Development</i> , 2019, 45, 702-708.	0.8	12
40	Responding to the Zika Epidemic: Preparation of a Neurodevelopmental Testing Protocol to Evaluate Young Children in Rural Guatemala. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 438-444.	0.6	12
41	Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. <i>Vaccine</i> , 2014, 32, 6284-6293.	1.7	10
42	Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. <i>Vaccine</i> , 2017, 35, 923-928.	1.7	10
43	Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. <i>Vaccine Journal</i> , 2016, 23, 326-338.	3.2	9
44	Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. <i>Journal of Infectious Diseases</i> , 2022, 226, 1731-1742.	1.9	8
45	CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 773-775.	0.3	7
46	Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. <i>Vaccine</i> , 2019, 37, 2561-2568.	1.7	6
47	Clinical data on Fluarix [®] : an inactivated split seasonal influenza vaccine. <i>Expert Review of Vaccines</i> , 2008, 7, 713-719.	2.0	5
48	Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. <i>Journal of Infectious Diseases</i> , 2021, 224, 1712-1719.	1.9	5
49	<i>Arcanobacterium haemolyticum</i> Central Nervous System Abscess and Bacteremia Following Head Trauma. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, e9-e11.	0.1	4
50	An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3138-3145.	1.4	4
51	Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. <i>Vaccine</i> , 2015, 33, 163-173.	1.7	3
52	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2: a review. <i>Translational Research</i> , 2022, 242, 1-19.	2.2	3
53	Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. <i>JAMA Network Open</i> , 2022, 5, e2215984.	2.8	3
54	Recombinant hemagglutinin protein vaccine: a new option in immunization against influenza. <i>Future Virology</i> , 2015, 10, 1057-1067.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Mycobacterium avium complex-associated cholecystitis in AIDS patient: a case description and review of literature. International Journal of STD and AIDS, 2016, 27, 1218-1222.	0.5	2
56	Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. Vaccine, 2021, 39, 1339-1348.	1.7	2
57	Sensitive and Prolonged Detection of Dengue Virus RNA in Whole Blood. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1734-1736.	0.6	2
58	A prospective cohort study of head circumference and its association with neurodevelopmental outcomes in infants and young children in rural Guatemala. Journal of Developmental Origins of Health and Disease, 2022, 13, 779-786.	0.7	2
59	Performance of Xpert MTB/RIF in Induced Sputum Samples at Detecting Mycobacterium Tuberculosis. Clinical Infectious Diseases, 2014, 59, 911-912.	2.9	1
60	Occupational Exposure to the Ugandan Research Strain (MR766) of Zika Virus. Open Forum Infectious Diseases, 2019, 6, ofz420.	0.4	1
61	CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV – ERRATUM. Canadian Journal of Neurological Sciences, 2020, 47, 151-151.	0.3	1
62	Parent Report of Health Related Quality of Life in Young Children in Rural Guatemala: Implementation, Reliability, and Validity of the PedsQL in Stunting and Wasting. Global Pediatric Health, 2021, 8, 2333794X2199102.	0.3	1
63	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infectious Diseases, 0, , .	0.4	1
64	2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients. Open Forum Infectious Diseases, 2018, 5, S748-S748.	0.4	0
65	The Reply. American Journal of Medicine, 2019, 132, e668.	0.6	0
66	2801. Post-Natal Zika Virus Infection and Impact on Neurodevelopment Among a Cohort of Children in Rural Guatemala. Open Forum Infectious Diseases, 2019, 6, S990-S991.	0.4	0
67	846. Postnatally Acquired Zika Virus (ZIKV) Infection in Infants and Young Children in Guatemala: Serologic and Neurodevelopmental (ND) Evaluation. Open Forum Infectious Diseases, 2019, 6, S14-S15.	0.4	0
68	757. Association between cumulative febrile, respiratory and diarrheal illness in the first year of life and neurodevelopmental and growth outcomes among a cohort of children in rural Guatemala. Open Forum Infectious Diseases, 2020, 7, S425-S426.	0.4	0
69	1407. Cytomegalovirus (CMV) infection in the first year of life in a cohort of infants in rural Guatemala. Open Forum Infectious Diseases, 2020, 7, S711-S712.	0.4	0